London, 7 November 2017, Consilium Strategic Communications, a global leader in strategic healthcare communications, announces that it advises Ablynx NV (“Ablynx”), and was part of the syndicate working on its successful $200 million Initial Public Offering (“IPO”) on NASDAQ.
Ablynx announced on 27 October 2017 that it had successfully closed an IPO on NASDAQ, raising a total of $200 million, with an additional $30 million following a green shoe exercise. This was up from an initial target of $150 million. The transaction was the largest biotech IPO in the U.S. this year, with Ablynx seeing interest from a broad range of new and existing US investors.
Ablynx’s ordinary shares are listed on Euronext Brussels under the symbol “ABLX” and began trading on the NASDAQ Global Select Market on 25 October 2017 under the symbol “ABLX.”
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals.
“Our recent listing on NASDAQ was a great success with the book almost three times over-subscribed in relation to our initial target. It has resulted in a significant increase in the quality and breadth of our investor base. It also provides us with the capital to drive our proprietary programmes forward, and to ensure that we continue to expand and develop our pipeline.”
Edwin Moses
CEO of Ablynx
“We are delighted to have advised Ablynx on its hugely successful IPO and US listing. We have a longstanding relationship with the company which first started in 2011. We have enjoyed working with the company as they have evolved into one of the world’s finest, global, commercial-stage biotech companies. We look forward to continuing to support Ablynx going forward.”
Mary-Jane Elliott
Managing Partner of Consilium Strategic Communications,
